Pharmacare’s Fiscal Arithmetic

The case for universal pharmacare is well established in the literature. Canada spends more per capita on prescription drugs than nearly every country with a universal drug plan, primarily because a fragmented public-private system lacks the monopsonistic buying power that single-payer plans exercise. A national formulary purchasing drugs at scale could theoretically reduce total system costs even while expanding coverage.

The federal government has committed to a phased implementation beginning with diabetes medications and contraceptives. Full implementation of a comprehensive universal formulary is estimated to cost the federal government $11–15 billion annually at steady state, partially offset by reduced private plan costs and provincial savings.

Why the Fiscal Path Is Narrow

That partial offset is where the complexity lies. Provincial governments currently administer their own drug benefit programs. A federal pharmacare program requires negotiating cost-sharing arrangements with provinces that have deeply different existing coverage levels, drug plan structures, and fiscal positions. Quebec, which already has a comprehensive provincial plan, has signalled it will demand full compensation for any federal program that overlaps with its existing system — a demand that significantly increases the federal net cost.

The Pharmaceutical Industry Response

Canada’s attractiveness as a market for innovative pharmaceutical launches is partly a function of its pricing environment. Single-payer systems that use their buying power aggressively — as a national pharmacare plan would — sometimes find that pharmaceutical companies delay or decline to launch new drugs in those markets. The trade-off between lower prices for existing drugs and timely access to innovative therapies is genuine and deserves honest public debate rather than rhetorical dismissal.